A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NCT07392190 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

900

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight
Obesity

Interventions

DRUG: Eloralintide
DRUG: Placebo

Sponsor

Eli Lilly and Company